Last reviewed · How we verify
Diagnostic aid — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Lymphoseek Kit | TECHNETIUM TC 99M TILMANOCEPT | Navidea Biopharms | Radioactive Diagnostic Agent | 2013-01-01 | ||
| Sincalide | SINCALIDE | Bracco | Cholecystokinin Analog [EPC] | Cholecystokinin receptor type A | 1976-01-01 | |
| Ipodate | iopodic acid | Bracco | iopodic acid | 1962-01-01 | ||
| Lymphoseek | Lymphoseek | Eben Rosenthal |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 4 drugs in Diagnostic aid
- Bracco · 2 drugs in Diagnostic aid
- Eben Rosenthal · 1 drug in Diagnostic aid
- Navidea Biopharms · 1 drug in Diagnostic aid
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Diagnostic aid:
- Diagnostic aid treatment updates — RSS
- Diagnostic aid treatment updates — Atom
- Diagnostic aid treatment updates — JSON
Cite this brief
Drug Landscape (2026). Diagnostic aid — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diagnostic-aid. Accessed 2026-06-10.
Related
- Diagnostic aid full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing